Digestive Diseases and Sciences

, Volume 51, Issue 11, pp 2031–2038

A Retrospective Search for Predictors of Clinical Response to Selective Granulocyte and Monocyte Apheresis in Patients With Ulcerative Colitis

  • Yasuo Suzuki
  • Naoki Yoshimura
  • Katsuyuki Fukuda
  • Koji Shirai
  • Yasushi Saito
  • Abbi R. Saniabadi
Original Paper


Recently, selective granulocytapheresis (Adacolumn) has appeared as a new treatment for patients with inflammatory bowel disease. This study sought to determine predictors of response to this new nonpharmacologic mode of therapy by retrospectively evaluating 28 patients who received granulocytapheresis after experiencing active ulcerative colitis (UC). Between April 2000 and March 2004, 28 consecutive patients received granulocytapheresis for active UC with the Adacolumn, which is filled with cellulose acetate beads as the column leukocytapheresis carriers; the carriers adsorb granulocytes, monocytes/macrophages, and a small fraction of lymphocytes (FcγR and complement receptors bearing leukocytes). Each patient could receive up to 10 Adacolumn sessions, at 2 sessions per week. In 2004, clinical response was retrospectively evaluated. Seven days after the last Adacolumn session, 20 of 28 patients had remission (colitis activity index [CAI] ≤4) including all 8 patients who had their first UC episode. The mean duration of UC in the 8 first episode cases was 3.4 months compared with 40.2 months for all 28 patients and 65.4 months for the 8 nonresponders. The response to Adacolumn was independent of basal CAI. The 8 nonresponders were given conventional medication (CM) or cyclosporine (CsA) if the former failed. Two responded to CM, 3 to CsA, and 3 underwent colectomy. First UC episode and short disease duration appear good predictors of response to granulocytapheresis. Selective granulocytapheresis might be an effective first-line treatment.


Ulcerative colitis First ulcerative colitis episode 5-ASA Selective granulocyte and monocyte adsorptive apheresis Prednisolone Clinical activity index Endoscopic activity index 


  1. 1.
    McCarthy DA, Rampton DS, Liu Y-C (1991) Peripheral blood neutrophils in inflammatory bowel disease. Morphological evidence of in vivo activation in active disease. Clin Exp Immunol 86:489–493PubMedCrossRefGoogle Scholar
  2. 2.
    Grisham MB, Yamada T (1992) Neutrophils, nitrogen oxides and inflammatory bowel disease, neuro-immuno-physiology of the gastrointestinal mucosa. Ann NY Acad Sci 664:103–115PubMedGoogle Scholar
  3. 3.
    Allison MC, Dhillon AP, Lewis WG, Pounder RE (eds) (1998) Inflammatory Bowel Disease. Mosby, London, pp 15–95Google Scholar
  4. 4.
    Tibble JA, Sigthorsson G, Bridger D (2000) Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119:15–22PubMedCrossRefGoogle Scholar
  5. 5.
    Bjarnason I, Macpherson A, Menzies IS (1994) Intestinal permeability: The basics. In: Sutherland LR, Collins SM, Martin F, McLeod RS, Targan SR, Wallace JL, Williams CN (eds) Inflammatory bowel disease. Basic research, clinical implications and trends in therapy. Kluwer Academic Press, Dordrech, pp 53–70Google Scholar
  6. 6.
    Bjarnason I, Macpherson A, Hollander D (1995) Intestinal permeability: an overview. Gastroenterology 108:1566–1581PubMedCrossRefGoogle Scholar
  7. 7.
    Cassatella MA (1995) The production of cytokines by polymorphonuclear neutrophils. Immunol Today 16:21–26PubMedCrossRefGoogle Scholar
  8. 8.
    Nikolaus S, Bauditz J, Gionchetti P (1998) Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut 142:470–476CrossRefGoogle Scholar
  9. 9.
    Hanai H, Watanabe F, Takeuchi K, Saniabadi A (2003) Leucocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective uncontrolled pilot study. Clin Gastroenterol Hepatol 1:28–35PubMedCrossRefGoogle Scholar
  10. 10.
    Brannigan AE, O’Connell PR, Hurley H (2000) Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock 13:361–366PubMedGoogle Scholar
  11. 11.
    Roseth AG, Schmidt PN, Fagerhol MK (1999) Correlation between faecal excretion of Indium-111-labelled granulocytes and calprotectin, a granulocyte marker. Scand J Gastroenterol 34:50–54PubMedCrossRefGoogle Scholar
  12. 12.
    Lee A, Whyte M, Haslett C (1993) Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol 283–288Google Scholar
  13. 13.
    Meagher LC, Cousin JM, Seckl JR, Haslett C (1996) Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 156:4422–4428PubMedGoogle Scholar
  14. 14.
    Ohara M, Saniabadi AR, Hirata I, Kasukawa R (1997) Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif Organs 21:989–994PubMedCrossRefGoogle Scholar
  15. 15.
    Saniabadi AR, Hanai H, Lofberg R (2003) Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 7:48–59PubMedCrossRefGoogle Scholar
  16. 16.
    Saniabadi AR, Hanai H, Suzuki Y, Lofberg R (2005) Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher 20:171–184PubMedCrossRefGoogle Scholar
  17. 17.
    Hiraishi K, Takeda Y, Shiobara N (2003) Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 7:334–340PubMedCrossRefGoogle Scholar
  18. 18.
    D’Arrigo C, Candal-Couto JJ, Greer M (1993) Human neutrophil Fc receptor-mediated adhesion under flow: a hallow fiber model of intravascular arrest. Clin Exp Immunol 100:173–179CrossRefGoogle Scholar
  19. 19.
    Rachmilewitz D, on behalf of an international study group (1989) Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J 298:82–86CrossRefGoogle Scholar
  20. 20.
    Hanai H, Watanabe F, Saniabadi A (2002) Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci 47:2349–2353PubMedCrossRefGoogle Scholar
  21. 21.
    Kanke K, Nakano M, Hiraishi H, Terano A (2004) Evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liv Dis 36:512–518CrossRefGoogle Scholar
  22. 22.
    Suzuki Y, Yoshimura N, Saniabadi AR (2004) Selective neutrophil and monocyte adsorptive apheresis as a first line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 49:565–571PubMedCrossRefGoogle Scholar
  23. 23.
    Cohen RD (2005) Treating ulcerative colitis without medications—“Look Mom, No Drugs!” Gastroenterology 128:235–236PubMedCrossRefGoogle Scholar
  24. 24.
    Agius LM (2004) A primary dysregulation in the immunoregulatory role of the intestinal mucosal epithelial cell in inflammatory bowel disease pathogenesis? Biology of inflammatory response as tissue pattern entities in Crohn's versus ulcerative colitis. J Theor Biol 227:219–228PubMedCrossRefGoogle Scholar
  25. 25.
    D’Haens G, Lemmens L, Geboes K (2001) Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 120:1323–1329PubMedCrossRefGoogle Scholar
  26. 26.
    Naganuma M, Funakoshi S, Sakuraba A (2004) Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 10:251–257PubMedCrossRefGoogle Scholar
  27. 27.
    Yamamoto T, Umegae S, Kitagawa T (2004) Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther 20:783–792PubMedCrossRefGoogle Scholar
  28. 28.
    Tomomasa T, Kobayashi A, Kaneko H (2003) Granulocyte adsorptive apheresis for pediatric patients with ulcerative colitis. Dig Dis Sci 48:750–754PubMedCrossRefGoogle Scholar
  29. 29.
    Premchand P, Takeuchi K, Bjarnason I (2004) Granulocyte, macrophage, monocyte apheresis for refractory ulcerative proctitis. Eur J Gastroenterol Hepatol 16:943–945PubMedCrossRefGoogle Scholar
  30. 30.
    Hanai H, Watanabe F, Yamada M (2004) Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 70:36–44PubMedCrossRefGoogle Scholar
  31. 31.
    Domenech E, Hinojosa J, Esteve-Comas M (2002) Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 20:1347–1352CrossRefGoogle Scholar
  32. 32.
    Kashiwagi N, Saniabadi A, Shimoyama T (2002) Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 47:1334–1341PubMedCrossRefGoogle Scholar
  33. 33.
    Tabuchi T, Saniabadi AR (1999) Granulocyte apheresis as a possible new approach in cancer therapy: a pilot study involving two cases. Cancer Detect Preven 23:417–421CrossRefGoogle Scholar
  34. 34.
    Bitton A, Peppercorn MA, Antonioli DA (2001) Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 120:13–20PubMedCrossRefGoogle Scholar
  35. 35.
    Irving PM, Rampton DS (2004) Leucocytapheresis for ulcerative colitis (commentary). Dig Liver Dis 36:799–802PubMedCrossRefGoogle Scholar
  36. 36.
    Biswas P, Mantelli B, Hasson H (2003) In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: implications for treatment of HIV infection and other immune disorders. Clin Immunol 109:355–358PubMedCrossRefGoogle Scholar
  37. 37.
    Hogg N, Berlin C (1995) Structure and function of adhesion receptors in leucocyte trafficking. Immunol Today 16:327–330PubMedCrossRefGoogle Scholar
  38. 38.
    Rottman JB, Smith TL, Ganley KG (2001) Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest 81:335–347PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Yasuo Suzuki
    • 1
    • 4
  • Naoki Yoshimura
    • 2
  • Katsuyuki Fukuda
    • 1
  • Koji Shirai
    • 1
  • Yasushi Saito
    • 2
  • Abbi R. Saniabadi
    • 3
  1. 1.Department of Internal Medicine, Sakura HospitalToho University, Chiba University School of MedicineTokyoJapan
  2. 2.Department of Internal MedicineSocial Insurance Chuo General Hospital, Chiba University School of MedicineTokyoJapan
  3. 3.Japan Immunoresearch LaboratoriesTakasakiJapan
  4. 4.Sakura Hospital, Faculty of MedicineToho UniversitySakura City, ChibaJapan

Personalised recommendations